This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

HQDA Elderly Life Network Valuation

Is HQDA undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HQDA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HQDA's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HQDA's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HQDA?

Key metric: As HQDA is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HQDA. This is calculated by dividing HQDA's market cap by their current revenue.
What is HQDA's PS Ratio?
PS Ratio	22.6x
Sales	US$825.26k
Market Cap	US$18.67m

HQDA key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	22.6x
Enterprise Value/EBITDA	118.9x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does HQDA's PS Ratio compare to its peers?

The above table shows the PS ratio for HQDA vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.1x
TOI Oncology Institute	0.03x	n/a	US$11.4m
IMTH Innovative MedTech	7.6x	n/a	US$13.4m
GRST Ethema Health	0.6x	n/a	US$3.9m
SSY SunLink Health Systems	0.2x	n/a	US$5.4m
HQDA HQDA Elderly Life Network	22.6x	n/a	US$18.7m

Price-To-Sales vs Peers: HQDA is expensive based on its Price-To-Sales Ratio (22.6x) compared to the peer average (18.8x).

Price to Sales Ratio vs Industry

How does HQDA's PS Ratio compare vs other companies in the US Healthcare Industry?

36 Companies	Price / Sales	Estimated Growth	Market Cap
MCK McKesson	0.2x	8.1%	US$78.29b
CVS CVS Health	0.2x	4.5%	US$75.61b
COR Cencora	0.2x	6.5%	US$47.87b
CNC Centene	0.2x	5.5%	US$31.01b

36 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Sales vs Industry: HQDA is expensive based on its Price-To-Sales Ratio (22.6x) compared to the US Healthcare industry average (1x).

Price to Sales Ratio vs Fair Ratio

What is HQDA's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HQDA PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	22.6x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate HQDA's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Patterson Companies

US$1.9b

Engages in the distribution of dental and animal health products in the United States, the United Kingdom, and Canada.

PDCO

US$21.49

5.3%

-31.6%

Centene

US$31.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$60.00

3.8%

-17.8%

Lantheus Holdings

US$6.3b

Develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide.

LNTH

US$89.53

12.7%

29.8%